Marginal effect of cetuximab on infection event using instrumental variable analysis for one-year follow-up (n = 611).

<p>Abbreviation: 95% CI, 95% confidence interval.</p

One-year cumulative risk of infection among the patients with cetuximab and those without (n = 1083)^a.

a<p>Stratum 1 had the strongest propensity for not receiving cetuximab therapy; stratum 5, for receiving cetuximab therapy.</p>b<p>Cochran-Mantel-Haenszel statistics; adjusted odds ratio = 2.27, 95% confidence interval = 1.46–3.54.</p

Infection rate head and neck cancer patients treated with different treatment modality.

*<p>P value of Pearson’s chi-square test between the cetuximab group v.s without cetuximab group is <0.001.</p

Distribution of explanatory variables between patients in high-use and low-use cetuximab hospitals (a) and infection rates (b).

<p>Distribution of explanatory variables between patients in high-use and low-use cetuximab hospitals (a) and infection rates (b).</p

Infectious complications in head and neck cancer patients.

<p>Infectious complications in head and neck cancer patients.</p

Characteristics of head and neck cancer patients in high-cetuximab and low-cetuximab use hospitals (n = 611).

*<p>Parenthesis is percentage of patients in high-use or low-use hospitals.</p

Infection events in study population (n = 1083).

<p>Infection events in study population (n = 1083).</p

Demographic characteristics for head and cancer patients by treatment modality (n = 1083).

<p>Demographic characteristics for head and cancer patients by treatment modality (n = 1083).</p

Distribution of explanatory variables between patients receiving cetuximab and those not receiving cetuximab for propensity score quintiles ranging from 1 (least likely to receive cetuximab) to 5 (most likely to receive cetxuimab).

<p>Distribution of explanatory variables between patients receiving cetuximab and those not receiving cetuximab for propensity score quintiles ranging from 1 (least likely to receive cetuximab) to 5 (most likely to receive cetxuimab).</p

AZD2014 inhibited cell proliferation in OSCC cell lines.

<p>SCC4 and SCC25 cell proliferation after treatment with AZD2014 (0 to 100 nM) 48 hours using the MTT assay. Data are the mean ± SD of three independent experiments performed in triplicate. SD = standard deviation. *p<0.05 compared to the vehicle control.</p